Indicated for: cancer
Route of administration: injectable / infusion
Substance: dacarbazine (alkylating antineoplastic agent)
ATC: L01AX04 (Antineoplastic and immunomodulating agents | Alkylating agents | Other alkylating agents)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Dacarbazine is a chemotherapy medication used for the treatment of malignant melanoma, Hodgkin's disease, and other types of cancer. It acts as an alkylating agent, interfering with DNA synthesis and inhibiting cell division.
The medication is administered via intravenous infusion, with the dose determined by the physician based on the type of cancer and the patient's overall condition. Common side effects include nausea, vomiting, fatigue, and bone marrow suppression.
Dacarbazine is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with hepatic or renal impairment.
This medication is an important option in cancer treatment, helping to reduce tumor size and improve the prognosis of affected patients.